Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Interstitial cystitis / bladder pain syndrome (IC/BPS) is a debilitating condition that
affects millions of women in the United States. Women suffer from recurring pelvic pain,
bladder pressure, painful bladder, urinary frequency (needing to go often) and urgency
(feeling a strong need to go). Women are five times more likely to suffer from IC/BPS than
men. IC/BPS is a common cause of painful bladder after excluding urinary tract infection.
About one-third of women resort to opioids, thus contributing to the current opioid crisis.
Sadly, there are no durable treatments and the majority of therapies are not FDA-approved for
IC/BPS.
Phase:
Early Phase 1
Details
Lead Sponsor:
Stanford University
Collaborator:
McCormick and Gabilan Faculty Fellowship Award
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A